Cidara Therapeutics Inc

Merck’s Merger Mops Cidara’s Shareholder Tangle: RA Capital Executes Zero‑Cost Buy‑Sell to Seamlessly Transfer 1.3 M Shares for $221.50 Each, Signaling End of Public Trade and Insider Wind‑Down <|end|>

Merger‑driven insider moves at Cidara reveal how RA Capital streamlined its holdings for Merck, turning shares into cash and ending public trading.

DirectorDealingsBot

10/01/2026, 00:58

4 minutes to read

RA Capital’s $221.50‑per‑Share Cashless Warrant Exercise Clears the Deck for Merck’s Takeover of Cidara Therapeutics

Merck’s Cidara takeover reaches a milestone as RA Capital swaps cashless warrants for $221.50 per share, confirming a clean exit and full insider alignment.

DirectorDealingsBot

09/01/2026, 23:29

4 minutes to read

Insider Surge: Cidara Executives Dump 500,000+ Shares as Merck Merger Winds Down—What It Means for Investors

Merck’s Merck‑Cidara merger sparks a wave of insider option sales, boosting liquidity but raising questions on future alignment and investor confidence.

DirectorDealingsBot

08/01/2026, 02:36

9 minutes to read

Cidara Therapeutics Inc

Merck’s Merger Mops Cidara’s Shareholder Tangle: RA Capital Executes Zero‑Cost Buy‑Sell to Seamlessly Transfer 1.3 M Shares for $221.50 Each, Signaling End of Public Trade and Insider Wind‑Down <|end|>

RA Capital’s $221.50‑per‑Share Cashless Warrant Exercise Clears the Deck for Merck’s Takeover of Cidara Therapeutics

Insider Surge: Cidara Executives Dump 500,000+ Shares as Merck Merger Winds Down—What It Means for Investors

Merck’s Merger Mops Cidara’s Shareholder Tangle: RA Capital Executes Zero‑Cost Buy‑Sell to Seamlessly Transfer 1.3 M Shares for $221.50 Each, Signaling End of Public Trade and Insider Wind‑Down <|end|>

RA Capital’s $221.50‑per‑Share Cashless Warrant Exercise Clears the Deck for Merck’s Takeover of Cidara Therapeutics